ANAB - CIK 0001370053
The table below shows ANAPTYSBIO, INC's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $248.47M | $109.83M | $44.30M | $98.64M | $191.58M | $71.82M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $316.11M |
| $330.65M |
| $291.91M |
| $363.11M |
| $448.68M |
| $367.35M |
| Property, plant & equipment | $1.28M | $1.50M | $1.63M | $1.74M | $1.73M | $1.83M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $329.68M | $353.10M | $335.25M | $422.05M | $493.42M | $427.38M |
| Accounts payable | $7.52M | $2.89M | $3.33M | $6.12M | $3.59M | $4.89M |
| Total current liabilities | $41.70M | $38.10M | $35.53M | $44.04M | $43.88M | $40.42M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | -$825.44M | -$822.17M | -$837.29M | -$798.66M | -$737.54M | -$704.69M |
| Total equity | $12.75M | -$29.42M | -$44.73M | $34.02M | $84.37M | $9.88M |